Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient­Reported Outcomes in Patients with Early Relapsing­Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4­year, Real­World, Open­Label Study.

Perumal, Jai; Balabanov, Roumen; Su, Ray; Chang, Roger; Balcer, Laura J; Galetta, Steven L; Avila, Robin L; Rutledge, Danette; Fox, Robert J

Correction to: Improvements in Cognitive Processing Speed, Disability, and PatientReported Outcomes in Patients with Early RelapsingRemitting Multiple Sclerosis Treated with Natalizumab: Results of a 4year, RealWorld, OpenLabel Study.

Perumal, Jai; Balabanov, Roumen; Su, Ray; Chang, Roger; Balcer, Laura J; Galetta, Steven L; Avila, Robin L; Rutledge, Danette; Fox, Robert J.

Afiliação

Perumal J; Weill Cornell Medical College, Cornell University, 1305 York Ave #2F, New York, NY, 10065, USA. jaisperumal@gmail.com.
Balabanov R; Northwestern University, Chicago, IL, USA.
Su R; Biogen, Cambridge, MA, USA.
Chang R; Biogen, Cambridge, MA, USA.
Balcer LJ; New York University Grossman School of Medicine, New York, NY, USA.
Galetta SL; New York University Grossman School of Medicine, New York, NY, USA.
Avila RL; Biogen, Cambridge, MA, USA.
Rutledge D; Biogen, Cambridge, MA, USA.
Fox RJ; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.

CNS Drugs ; 37(3): 275-289, 2023 Mar.

Article em En | MEDLINE | ID: mdl-36780107

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: CNS Drugs Assunto da revista: FARMACOLOGIA / NEUROLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google